Ro vs Henry Meds: Two Telehealth GLP-1 Models Compared

This article is part of the PlexusDx Education Hub, our evidence-based coverage of GLP-1 therapy, weight management protocols, and the genetics that shape metabolic outcomes. Browse all Peptides & GLP-1 education

This is independent editorial analysis. PlexusDx has no commercial relationship with Ro or Henry Meds, carries no affiliate links, and earns nothing from either mention.

Full head-to-head: PlexusDx vs Henry Meds →

Searches for "Ro vs Henry Meds" tend to weigh a large, multi-condition telehealth brand against a narrower compounding-focused program. This editorial compares the two on model, medication routing, and cost, then names the genetic factor neither company screens. As of April 2026 the GLP-1 telehealth landscape holds dozens of players; here we stay on Ro and Henry Meds.

Big platform versus focused program

The core contrast is scale and focus. Ro is a broad subscription telehealth platform serving many needs, while Henry Meds concentrates on compounded GLP-1 care. That shapes the experience: a wide-catalog membership versus a program built specifically around GLP-1 dispensing.

Where Ro fits

Ro (Roman Health) operates as subscription telehealth. Like others in this model, it can involve virtual clinical evaluation, provider-issued prescriptions, and either brand-name FDA-approved GLP-1 dispensing or compounded semaglutide and tirzepatide through licensed compounding pathways. Confirm current program details at Ro's official website.

Where Henry Meds fits

Henry Meds pairs telehealth with a compounding-pharmacy pathway, with program terms, medication options, and pricing that shift over time. For the current picture, consult Henry Meds's official website whenever you evaluate it.

What moves the price on each

Monthly totals across GLP-1 telehealth in 2026 commonly range from about $200 to $700 or more once program fees, medication, and compounded dispensing are included. A large platform and a focused program can price differently based on catalog, subscription structure, and whether brand or compounded formulations are routed. Ro and Henry Meds each publish their own numbers, so verify current pricing directly on each brand's page rather than relying on a figure that may already be outdated.

Scale does not change the pharmacology

Whether the prescriber is a big platform or a focused clinic, the drug's action comes from the compound. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide influence appetite, satiety, and gastric emptying. The evidence tracks the molecules: STEP for semaglutide in weight management (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM 2024). Results vary by dose, compound, and individual.

The variable no platform, large or small, maps

Neither a big platform nor a focused program examines the inherited biology a GLP-1 drug meets. GLP1R encodes the receptor these compounds bind, FTO shapes fat-mass and obesity risk, MC4R governs satiety and energy balance, and TCF7L2 ties to glucose regulation and GLP-1 secretion. These pathway-level variants describe terrain, not a predicted response. PlexusDx pairs its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the Precision Peptide Genetic Test, reading 14 pathways, 49 peptides, 150+ genetic insights across FTO, MC4R, and TCF7L2. It is the test before you invest approach: map your baseline, then decide with your provider.

Not affiliated: PlexusDx has no affiliation with Ro or Henry Meds and no commercial tie to any company reviewed here.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Disclaimer: This article is educational. PlexusDx is not affiliated with Ro or Henry Meds and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Explore the PlexusDx approach: the Weight Management Protocols, or start with the Precision Peptide Genetic Test to map your GLP-1 pathway first.

Frequently Asked Questions

Is Ro bigger than Henry Meds?

Ro is a broad, multi-condition telehealth platform, while Henry Meds is a narrower program focused on compounded GLP-1 care. Size and scope differ, but neither factor determines clinical results. Fit depends on the medication routing, subscription structure, and support each offers. Review both on their own sites.

Do Ro and Henry Meds prescribe compounded or brand GLP-1?

Both can route either brand-name FDA-approved products or compounded semaglutide and tirzepatide through licensed compounding pharmacies, depending on eligibility and availability. The dispensing pathway determines the formulation, not the size of the platform. Confirm which route applies during each program's intake process.

Can the Precision Peptide Genetic Test tell me which platform is better?

No. It does not predict response to Ro, Henry Meds, or any compound. It reports pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 biology — upstream context that stays relevant no matter which platform prescribes the medication.

Where does PlexusDx sit relative to Ro and Henry Meds?

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols and pairs them with the Precision Peptide Genetic Test. The differentiator is pathway-level genetic context on FTO, MC4R variants, which large platforms like Ro and focused programs like Henry Meds do not offer with the medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education